GlassScriptPhysician profile
Sandra Lynn Till
NPI 1164658761
$3,222.53
in general payments reported to CMS, 2019-2025
31 companies · $932 in 2025
The $932 reported for 2025 was more than what 76% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $179 · 2021: $344 · 2022: $221 · 2023: $723 · 2024: $675 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,309 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.27 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $436.16 | 2020-2025 | Trelegy Ellipta, Nucala |
| Insmed, INC. | $361.94 | 2019-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $231.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $225.48 | 2022-2025 | Tagrisso, Breztri, Fasenra |
| Intuitive Surgical, INC. | $224.76 | 2023 | |
| Abiomed | $172.64 | 2024-2025 | Impella |
| Penumbra, INC. | $165.69 | 2025 | Indigo System |
| Grifols USA, LLC | $163.52 | 2020-2024 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $99.85 | 2021-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $98.53 | 2020-2023 | Glassia |
| Actelion Pharmaceuticals US, INC. | $92.92 | 2020-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $83.72 | 2022-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $83.26 | 2024-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $77.63 | 2020-2025 | Zerbaxa |
| Viatris Specialty LLC | $77.33 | 2025 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74.05 | 2022-2024 | Tezspire |
| Jazz Pharmaceuticals INC. | $72.28 | 2023 | |
| Genzyme Corporation | $70.52 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $52.63 | 2022-2024 | Dupixent |
| Csl Behring | $47.83 | 2024 | Kcentra |
| Pulmonx Corporation | $42.40 | 2021-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Philips North America LLC | $41.74 | 2021-2025 | Incourage Airway Clearance Therapy |
| Inspire Medical Systems, INC. | $37.80 | 2025 | Inspire |
| Advanced Respiratory, INC | $36.36 | 2021 | |
| Verona Pharma, INC. | $30.02 | 2025 | Ohtuvayre |
| Ucb, INC. | $28.33 | 2024 | Bimzelx |
| Vifor Pharma, INC. | $21.78 | 2024 | Zemaira |
| Cmp Pharma, INC. | $21.16 | 2024 | Atorvaliq, Carospir, Norliqva |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.34 | 2020 | |
| Janssen Pharmaceuticals, INC | $17.24 | 2019 | |
| Baxter Healthcare | $14.56 | 2024 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Till listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.